Skip to content

Alkermes ALKS Research And Development — Contract With Customer Liability Revenue Recognized

Discontinued — last reported Q3 '18

Similar metrics at other companies

BridgeBio Pharma logo
BBIOResearch and Development Services — Contract with customer, liability
$2.7M
Protagonist Therapeutics logo
PTGXDevelopment Services — Contract With Customer Liability Revenue Recognized
$3.3M
RBC Bearings logo
RBCContract With Customer Liability Revenue Recognized
$24.4M+34.8%
Ionis Pharmaceuticals logo
IONSResearch And Development Revenue — Revenue
$138.28M+149%
BridgeBio Pharma logo
BBIOResearch and Development Services — Deferred revenue, current portion
$800K
Ionis Pharmaceuticals logo
IONSContract With Customer Liability Revenue Recognized
$19.6M-52.8%

Other financials

Income statement

See full
Revenue$392.9M+28.2%
Gross profit$331.3M+28.8%
Operating income-$48.3M-450%
Net income-$66.5M-396%
EPS (diluted)-$0.40-408%

Balance sheet

See full
Cash & equivalents$351.6M-12.1%
Total debt$1.6B+2,034%
Total equity$1.8B+15.9%
Total assets$4.3B+105%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$4.1M-59.5%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$7.5B+9.7%
Enterprise value$8.73B+41.2%
P/E49.1×+29.7×
P/S4.8×+0.3×

Profitability

See full
Gross margin86.6%+2.2pp
Operating margin12.3%-13.6pp
Net margin9.8%-13.5pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity9.4%-16.1pp
Debt / equity0.9×+0.9×
Current ratio2.3×-1.1×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityRevenueRecognized.

The official record: Alkermes’s 10-Q, filed October 23, 2018, on SEC EDGAR. View the filing →

Questions, answered.

What does research and development — contract with customer liability revenue recognized mean?
This metric tracks the amount of revenue recognized during the period that was previously recorded as a contract liability (deferred revenue). It reflects the conversion of upfront payments or prepayments into earned revenue as the company fulfills its research and development obligations. This metric helps investors understand the pace at which the company is delivering on its contractual commitments.